Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis.
Am J Trop Med Hyg
; 95(4): 800-802, 2016 10 05.
Article
en En
| MEDLINE
| ID: mdl-27481058
ABSTRACT
Visceral leishmaniasis (VL) diagnosis is routinely performed by invasive liver, spleen, bone marrow, or lymph node biopsies, followed by microscopic identification of the parasites. Conventional serological tests cannot distinguish active disease from asymptomatic VL or from cured infection. Here, we report the initial validation of an enzyme-linked immunosorbent assay (ELISA) assembled to detect the Leishmania infantum/donovani antigens iron superoxide dismutase 1 (Li-isd1), tryparedoxin 1 (Li-trx1), and nuclear transport factor 2 (Li-ntf2) as a tool to monitor therapeutic efficacy of VL. The assembled ELISA detected the antigens in the urine samples from seven VL patients before initiation of therapy. Importantly, the antigens were no longer detected in all patients after completion of the treatment. These preliminary observations point to a promising tool to follow treatment efficacy of VL.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Antiprotozoarios
/
Proteínas Protozoarias
/
Leishmania infantum
/
Leishmaniasis Visceral
/
Antígenos de Protozoos
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Am J Trop Med Hyg
Año:
2016
Tipo del documento:
Article